FusionGDB Logo

Home

Download

Statistics

Examples

Help

Contact

Center for Computational Systems Medicine
leaf

Fusion Gene Summary

leaf

Fusion Gene ORF analysis

leaf

Fusion Genomic Features

leaf

Fusion Protein Features

leaf

Fusion Gene Sequence

leaf

Fusion Gene PPI analysis

leaf

Related Drugs

leaf

Related Diseases

Fusion gene:TAF13-LYPLA1 (FusionGDB2 ID:88723)

Fusion Gene Summary for TAF13-LYPLA1

check button Fusion gene summary
Fusion gene informationFusion gene name: TAF13-LYPLA1
Fusion gene ID: 88723
HgeneTgene
Gene symbol

TAF13

LYPLA1

Gene ID

6884

10434

Gene nameTATA-box binding protein associated factor 13lysophospholipase 1
SynonymsMRT60|TAF(II)18|TAF2K|TAFII-18|TAFII18APT-1|APT1|LPL-I|LPL1|hAPT1
Cytomap

1p13.3

8q11.23

Type of geneprotein-codingprotein-coding
Descriptiontranscription initiation factor TFIID subunit 13TAF13 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 18kDaTATA box binding protein (TBP)-associated factor, RNA polymerase II, K, 18kDtranscription initiation factor TFIID 18 kD subuacyl-protein thioesterase 1lysoPLA Ilysophospholipase Ilysophospholipid-specific lysophospholipase
Modification date2020031320200313
UniProtAcc.

O75608

Ensembl transtripts involved in fusion geneENST00000338366, ENST00000519926, 
ENST00000522007, ENST00000316963, 
ENST00000343231, 
Fusion gene scores* DoF score5 X 5 X 4=1005 X 4 X 3=60
# samples 64
** MAII scorelog2(6/100*10)=-0.736965594166206
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(4/60*10)=-0.584962500721156
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Context

PubMed: TAF13 [Title/Abstract] AND LYPLA1 [Title/Abstract] AND fusion [Title/Abstract]

Most frequent breakpointTAF13(109617609)-LYPLA1(54967693), # samples:2
Anticipated loss of major functional domain due to fusion event.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID

check buttonFusion gene breakpoints across TAF13 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across LYPLA1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check button Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
SourceDiseaseSampleHgeneHchrHbpHstrandTgeneTchrTbpTstrand
ChimerDB4SARCTCGA-3B-A9HS-01ATAF13chr1

109617609

-LYPLA1chr8

54967693

-


Top

Fusion Gene ORF analysis for TAF13-LYPLA1

check button Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
ORFHenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrand
5CDS-5UTRENST00000338366ENST00000519926TAF13chr1

109617609

-LYPLA1chr8

54967693

-
5CDS-intronENST00000338366ENST00000522007TAF13chr1

109617609

-LYPLA1chr8

54967693

-
In-frameENST00000338366ENST00000316963TAF13chr1

109617609

-LYPLA1chr8

54967693

-
In-frameENST00000338366ENST00000343231TAF13chr1

109617609

-LYPLA1chr8

54967693

-

check buttonORFfinder result based on the fusion transcript sequence of in-frame fusion genes.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000338366TAF13chr1109617609-ENST00000316963LYPLA1chr854967693-225516110567185
ENST00000338366TAF13chr1109617609-ENST00000343231LYPLA1chr854967693-122616110567185

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000338366ENST00000316963TAF13chr1109617609-LYPLA1chr854967693-0.0031362790.9968637
ENST00000338366ENST00000343231TAF13chr1109617609-LYPLA1chr854967693-0.0021267490.9978733

Top

Fusion Genomic Features for TAF13-LYPLA1


check buttonFusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.
HgeneHchrHbpHstrandTgeneTchrTbpTstrand1-pp (fusion gene breakpoint)

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.
genomic feature

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page.

Top

Fusion Protein Features for TAF13-LYPLA1


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr1:109617609/chr8:54967693)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonMain function of each fusion partner protein. (from UniProt)
HgeneTgene
.LYPLA1

O75608

FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}.FUNCTION: Acts as a acyl-protein thioesterase (PubMed:19439193, PubMed:20418879). Hydrolyzes fatty acids from S-acylated cysteine residues in proteins such as trimeric G alpha proteins or HRAS (PubMed:20418879). Has depalmitoylating activity toward KCNMA1 (PubMed:22399288). Could also depalmitoylate ADRB2 (PubMed:27481942). Acts as a lysophospholipase and hydrolyzes lysophosphatidylcholine (lyso-PC) (PubMed:19439193). Also hydrolyzes lysophosphatidylethanolamine (lyso-PE), lysophosphatidylinositol (lyso-PI) and lysophosphatidylserine (lyso-PS) (By similarity). Has much higher thioesterase activity than lysophospholipase activity (PubMed:19439193). Contributes to the production of lysophosphatidic acid (LPA) during blood coagulation by recognizing and cleaving plasma phospholipids to generate lysophospholipids which in turn act as substrates for ENPP2 to produce LPA (PubMed:21393252). {ECO:0000250|UniProtKB:P70470, ECO:0000269|PubMed:19439193, ECO:0000269|PubMed:20418879, ECO:0000269|PubMed:21393252, ECO:0000269|PubMed:22399288, ECO:0000269|PubMed:27481942}.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at

download page


* Minus value of BPloci means that the break pointn is located before the CDS.
- In-frame and retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

- In-frame and not-retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneTAF13chr1:109617609chr8:54967693ENST00000338366-2431_7435125.0DomainHistone-fold


Top

Fusion Gene Sequence for TAF13-LYPLA1


check button For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.
>88723_88723_1_TAF13-LYPLA1_TAF13_chr1_109617609_ENST00000338366_LYPLA1_chr8_54967693_ENST00000316963_length(transcript)=2255nt_BP=161nt
GTGTAACCAGCTGGGAGCCAGCCGGCAGGACGCTGTGAGTTGGCGTGCTAGTGGGATGGCAGATGAGGAAGAAGACCCCACGTTTGAGGA
AGAAAATGAAGAAATTGGAGGAGGTGCAGAAGGTGGACAGGGTAAAAGAAAGAGACTTTTTTCTAAAGAATTAAAAGCTTTGATTGATCA
AGAAGTGAAGAATGGCATTCCTTCTAACAGAATTATTTTGGGAGGGTTTTCTCAGGGAGGAGCTTTATCTTTATATACTGCCCTTACCAC
ACAGCAGAAACTGGCAGGTGTCACTGCACTCAGTTGCTGGCTTCCACTTCGGGCTTCCTTTCCACAGGGTCCTATCGGTGGTGCTAATAG
AGATATTTCTATTCTCCAGTGCCACGGGGATTGTGACCCTTTGGTTCCCCTGATGTTTGGTTCTCTTACGGTGGAAAAACTAAAAACATT
GGTGAATCCAGCCAATGTGACCTTTAAAACCTATGAAGGTATGATGCACAGTTCGTGTCAACAGGAAATGATGGATGTCAAGCAATTCAT
TGATAAACTCCTACCTCCAATTGATTGACGTCACTAAGAGGCCTTGTGTAGAAGTACACCAGCATCATTGTAGTAGAGTGTAAACCTTTT
CCCATGCCCAGTCTTCAAATTTCTAATGTTTTGCAGTGTTAAAATGTTTTGCAAATACATGCCAATAACACAGATCAAATAATATCTCCT
CATGAGAAATTTATGATCTTTTAAGTTTCTATACATGTATTCTTATAAGACGACCCAGGATCTACTATATTAGAATAGATGAAGCAGGTA
GCTTCTTTTTTCTCAAATGTAATTCAGCAAAATAATACAGTACTGCCACCAGATTTTTTATTACATCATTTGAAAATTAGCAGTATGCTT
AATGAAAATTTGTTCAGGTATAAATGAGCAGTTAAGATATAAACAATTTATGCATGCTGTGACTTAGTCTATGGATTTATTCCAAAATTG
CTTAGTCACCATGCAGTGTCTGTATTTTTATATATGTGTTCATATATACATAATGATTATAATACATAATAAGAATGAGGTGGTATTACA
TTATTCCTAATAATAGGGATAATGCTGTTTATTGTCAAGAAAAAGTAAAATCGTTCTCTTCAATTAATGGCCCTTTTATTTTGGGACCAG
GCTTTTATTTTCCCTGATATTATTTCTATTTAATACTCTTTTCTCTCAAGAAAAAAAAAAAAGTTTGTTTTTTCTTTATTGTCCTTCATA
GCAGGCCAAGTATTGCCTCTCTGCAATAGACAGCTACTGTCAATACATGCTGTAATTTGACATTCTGGGTCACAGATATAAGGTATTTAA
AATCTATTTATGCTTTATAGAGAAACCAGACATTAAAACTTCATGCACTACTTATTTCGAATTACTGTACCTTATCCAAATTTACACCTA
GCTATTAGGATCTTCAACCCAGGTAACAGGAATAATTCTGTGGTTTCATTTTTCTGTAAACAACTGAAAGAATAATTAGATCATATTCTA
GTATGTTCTGAAATATCTTTAAGACTGATCTTAAAAACTAACTTCTAAGATGATTTCATCTTCTCATAGTATAGAGTTTACTTTGTACAC
GTTTGAAACCAACTACTGTAGAAGATGAGGAATCTATTGTAATTTTTTGCTTTATTTTCATCTGCCAGTGGACTTATTTGAAATTTTCAC
TTTAGTCAAATTATTTTTTGTATTAGTTTTTGATGCAGACATAAAAATAGCAATCATTTTAAATTGTCAAAATTTCCAGATTACTGGTAA
AAATTATTTGAAAACAAACTTATGGGTAATAAAGGCTAGTCAGAACCCTATACCATAAAGTGTAGTTACCATACAGATTAATATGTAGCA
AAAATGTATGCTTGATATTTCTCAACTGTGTTAATTTTTCTGCTGTATTCCAGCTGACCAAAACAATATTAAGAATGCATCTTTATAAAT
GGGTGCTAATTGATAATGGAAATAATTTAGTAATGGACTATACAGGATGTTAATAATGAAGCCATATGTTTATGTCTGGATTTAAAAATT
TTAAACAATCATTTACTATGTCATTTTTCTTTACCTTGAAGAACATAAACTGTTATTTCACTTCTACAAATCAGCAAGATATTATTTATG
GCAAGAAATATTCCATTGAAATATTGTGCTGTAACATGGGAAAGTGTAAATGTTTTTCATGGTTTCTATCAATGTGAAATAAAATTTAAT

>88723_88723_1_TAF13-LYPLA1_TAF13_chr1_109617609_ENST00000338366_LYPLA1_chr8_54967693_ENST00000316963_length(amino acids)=185AA_BP=51
MGASRQDAVSWRASGMADEEEDPTFEEENEEIGGGAEGGQGKRKRLFSKELKALIDQEVKNGIPSNRIILGGFSQGGALSLYTALTTQQK
LAGVTALSCWLPLRASFPQGPIGGANRDISILQCHGDCDPLVPLMFGSLTVEKLKTLVNPANVTFKTYEGMMHSSCQQEMMDVKQFIDKL

--------------------------------------------------------------
>88723_88723_2_TAF13-LYPLA1_TAF13_chr1_109617609_ENST00000338366_LYPLA1_chr8_54967693_ENST00000343231_length(transcript)=1226nt_BP=161nt
GTGTAACCAGCTGGGAGCCAGCCGGCAGGACGCTGTGAGTTGGCGTGCTAGTGGGATGGCAGATGAGGAAGAAGACCCCACGTTTGAGGA
AGAAAATGAAGAAATTGGAGGAGGTGCAGAAGGTGGACAGGGTAAAAGAAAGAGACTTTTTTCTAAAGAATTAAAAGCTTTGATTGATCA
AGAAGTGAAGAATGGCATTCCTTCTAACAGAATTATTTTGGGAGGGTTTTCTCAGGGAGGAGCTTTATCTTTATATACTGCCCTTACCAC
ACAGCAGAAACTGGCAGGTGTCACTGCACTCAGTTGCTGGCTTCCACTTCGGGCTTCCTTTCCACAGGGTCCTATCGGTGGTGCTAATAG
AGATATTTCTATTCTCCAGTGCCACGGGGATTGTGACCCTTTGGTTCCCCTGATGTTTGGTTCTCTTACGGTGGAAAAACTAAAAACATT
GGTGAATCCAGCCAATGTGACCTTTAAAACCTATGAAGGTATGATGCACAGTTCGTGTCAACAGGAAATGATGGATGTCAAGCAATTCAT
TGATAAACTCCTACCTCCAATTGATTGACGTCACTAAGAGGCCTTGTGTAGAAGTACACCAGCATCATTGTAGTAGAGTGTAAACCTTTT
CCCATGCCCAGTCTTCAAATTTCTAATGTTTTGCAGTGTTAAAATGTTTTGCAAATACATGCCAATAACACAGATCAAATAATATCTCCT
CATGAGAAATTTATGATCTTTTAAGTTTCTATACATGTATTCTTATAAGACGACCCAGGATCTACTATATTAGAATAGATGAAGCAGGTA
GCTTCTTTTTTCTCAAATGTAATTCAGCAAAATAATACAGTACTGCCACCAGATTTTTTATTACATCATTTGAAAATTAGCAGTATGCTT
AATGAAAATTTGTTCAGGTATAAATGAGCAGTTAAGATATAAACAATTTATGCATGCTGTGACTTAGTCTATGGATTTATTCCAAAATTG
CTTAGTCACCATGCAGTGTCTGTATTTTTATATATGTGTTCATATATACATAATGATTATAATACATAATAAGAATGAGGTGGTATTACA
TTATTCCTAATAATAGGGATAATGCTGTTTATTGTCAAGAAAAAGTAAAATCGTTCTCTTCAATTAATGGCCCTTTTATTTTGGGACCAG

>88723_88723_2_TAF13-LYPLA1_TAF13_chr1_109617609_ENST00000338366_LYPLA1_chr8_54967693_ENST00000343231_length(amino acids)=185AA_BP=51
MGASRQDAVSWRASGMADEEEDPTFEEENEEIGGGAEGGQGKRKRLFSKELKALIDQEVKNGIPSNRIILGGFSQGGALSLYTALTTQQK
LAGVTALSCWLPLRASFPQGPIGGANRDISILQCHGDCDPLVPLMFGSLTVEKLKTLVNPANVTFKTYEGMMHSSCQQEMMDVKQFIDKL

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for TAF13-LYPLA1


check button Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in

ChiPPI page.


check button Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)
HgeneHgene's interactorsTgeneTgene's interactors


check button - Retained PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenStill interaction with


check button - Lost PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


check button - Retained PPIs, but lost function due to frame-shift fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


Top

Related Drugs for TAF13-LYPLA1


check button Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)
PartnerGeneUniProtAccDrugBank IDDrug nameDrug activityDrug typeDrug status

Top

Related Diseases for TAF13-LYPLA1


check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource